“On the 12-month-old SHR model of cardiac hypertrophy, the augmenting effects of tedisamil at 10-6 and 3 x 10-6 M were reduced.”
“On the 21-month-old SHR model of heart failure, the augmenting effects of tedisamil at 10-6 and 3 x 10-6 M were further reduced.”
“The augmenting effect of tedisamil at 10-5 M was reduced to 47%.”